Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced the launch of a new global initiative, “Her Plan is Her Power,” to accelerate progress toward addressing the public health crisis of unplanned pregnancy. Annually, nearly 50% of pregnancies (approximately 121 million) around the world are estimated to be unplanned, leading to health risks and reduced educational and employment opportunities for mother and child – challenges which can span generations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005176/en/
Unplanned pregnancies are in part caused by a lack of access to contraceptive information and services. Globally, of the 257 million women who want to avoid pregnancy, almost 67% are not using any contraceptive method. In response, Organon’s multi-year effort (2023-2025) builds on previous programming launched in 2022 through the “Her Promise” ESG platform. This new effort includes a portfolio of programs, collaborations and investments designed to fuel public health solutions, address inequities, and accelerate progress to help ensure women have the power to plan their future.
The $30 million “Her Plan is Her Power” initiative aims to address and overcome gaps and barriers to reduce unplanned pregnancies and empower women and girls when it comes to their sexual and reproductive health (SRH). It builds on existing company initiatives, with new funding to support:
- A planned three-pronged collaboration with UNFPA, the United Nations sexual and reproductive health agency, to help reduce unplanned pregnancies focused on innovation, access and education, and financing and sustainability. Initial projects are planned to support the Equalizer: UNFPA Accelerator Fund, through the establishment of an innovation challenge to empower young people by increasing access to financing and training to enable innovations for SRH information, services and commodities; enhancing a digital SRH knowledge solution with ethical artificial intelligence capabilities to give information and analytics to frontline healthcare workers in low-resource settings; and support for the Equity 2030 Alliance to accelerate actions to normalize gender equity in science and technology with a focus on SRH and women-focused solutions.
- Inaugural launch of a global grants program that provides resources to organizations working in communities to create a local response and empower people when it comes to reducing unplanned pregnancies and taking control of their reproductive health. The first cohort of grantees includes organizations across 13 countries including Dominican Republic, South Korea, Germany, and Thailand.
- New funding and product donations to help improve access and outcomes related to unplanned pregnancy in select communities in the US. Initial planned NGO partners include Direct Relief and Power to Decide, with additional US-based organizations and communities to be announced later this year.
“Empowering women with broad contraceptive access and education is a fundamental driver of equity and helping women decide when – and if – they decide to start a family,” said Kevin Ali, CEO of Organon. “Organon is proud to launch ‘Her Plan is Her Power’ and work with others to focus our resources and target responses to help ensure all women and girls can plan their future.”
This announcement comes on International Women’s Day and on the sidelines of the 67th session of the United Nations Commission on the Status of Women, to raise awareness and spur action, because in this complex environment, there has never been a more critical moment to stand – and act – with her.
“UNFPA is very excited to be working with Organon to advance sexual and reproductive health and rights and choices,” says Ian McFarlane, the Director of the Division for Communications and Strategic Partnerships at UNFPA. “The staggering number of unintended pregnancies that occur globally each year – nearly half of all pregnancies – require the power of public-private collaboration. We look forward to continuing to build upon our efforts to help improve the lives of women and girls around the world.”
Organon is working to ensure that all women and girls achieve the full potential of their promise through better health. In 2022, Organon made a commitment to help prevent 120 million unplanned pregnancies in the world’s least-developed countries by 2030 as part of FP2030. Through “Her Plan is Her Power” the company will further accelerate progress towards this goal by working with global and local organizations across geographies with a focus on innovation, education, access, and advocacy.
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit https://www.organon.com/ and connect with us on LinkedIn, Instagram, Twitter and Facebook.
Except for historical information herein, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s launch of the “Her Plan is Her Power” global initiative. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2022, available at the SEC’s Internet site (www.sec.gov).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005176/en/
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abbove Awarded as Best Wealth Technology Outsourcing Solution in Europe30.3.2023 21:00:00 CEST | Press release
Abbove, the wealth planning technology platform was awarded as ‘best technology Outsourcing solution’ at WealthBriefing European Awards 2023. This news coincides with the milestone of 1000 wealth advisors using the platform to guide 30,000 families in achieving their wealth goals. The WealthBriefing Awards have been designed to recognize outstanding organizations grouped by specialism and geography, which the panel of independent judges deemed to have ‘demonstrated innovation and excellence during the last year’. The Belgian wealth-tech is not stopping there, as it now has over 1,000 wealth advisors from private banks and family offices using its technology to place holistic wealth advice at the center of their client relationship. Banking groups such as BNP Paribas Fortis, Quintet Bank or Deutsche Bank in Belgium are trusting Abbove to improve the way they manage, collect and process their client wealth data. Commenting on the firm’s triumph, Guillaume Desclée, CEO, Abbove said: "It’s
Verimatrix Gains EMVCo Security Evaluation Certificate as Software Protection Tool for Mobile Payment Apps30.3.2023 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD Code Shield toolkit for Android mobile applications received an EMVCo Security Evaluation Certificate as a Software Protection Tool (SPT). The designation demonstrates that Verimatrix’s technology mobile app security tool meets stringent payment security requirements. EMVCo is the global technical body that facilitates the worldwide interoperability and acceptance of secure payment transactions by managing and evolving the EMV® Specifications and related testing processes. Verimatrix gained the Security Evaluation Certificate following the completion of a robust evaluation by Riscure, a leading mobile security lab accredited by EMVCo. As one of Verimatrix’s latest efforts to further streamline the go-to-market process for Android app customers, the EMVCo Security Evaluation Certificate stands as a likely
H.I.G. Capital Acquires Synecore Limited and Meesons Futures Limited to Create the Andwis Group30.3.2023 17:03:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative asset investment firm with $55 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Synecore Limited (“Synecore”) and Meesons Futures Limited (“Meesons”). Synecore and Meesons will join forces with H.I.G.’s existing portfolio companies, CPS and Classic Lifts, to form the Andwis Group (the “Andwis” or the “Andwis Group”), a family of best-in-class technical services providers. The financial terms of the transactions have not been disclosed. Synecore specialises in the delivery and maintenance of HVAC, electrical, air conditioning, and refrigeration services to the hospitality, retail, leisure, and commercial sectors. Synecore, and its network of engineers and suppliers, provides both maintenance and installation services, often supporting site rollout and refurbishment programs. Founded in 1864, Meesons is a physical security and entrance control solutions provider for both crit
EMIT IMAGING Announces Appointment of Dr. Matthew Silva as Chief Executive Officer30.3.2023 16:10:00 CEST | Press release
EMIT IMAGING, Inc. (“EMIT” or the “Company”) is pleased to announce the appointment of Dr. Matthew Silva as the company's new Chief Executive Officer. EMIT IMAGINGis the world leader in Cryo-Fluorescence Tomography (CFT) imaging, an innovative imaging technology used by pharmaceutical, biotechnology, and academic researchers worldwide. EMIT’s imaging platform, XerraTM, is a state-of-the-art technology that provides high-sensitivity and high-resolution 3D fluorescence images of biological samples. Dr. Silva brings diverse experience and expertise in both science and business to the role, specifically drawing on technical training in biomedical engineering and previous executive positions in pharma and scientific services. Recently, Dr. Silva served as CEO of Invicro, LLC, an imaging contract research organization and subsidiary of REALM IDx/Konica Minolta. "We are thrilled to have Dr. Silva join the EMIT team," said Dr. Jack Hoppin, EMIT’sfounder and Chairman of the Board. "Matt has the
Stilla Technologies and Atila BioSystems to Co-Develop High-Plex Digital PCR Kits for Oncology30.3.2023 15:11:00 CEST | Press release
Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies). The digital PCR kits, optimized specifically for use with the 6-color naica® system, will be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients with high-occurring cancer indications such as breast, lung, melanoma, prostate, and colorectal cancers. The co-labeled digital PCR kits will be promoted globally by Atila and Stilla and will be designed For Research Use Only (RUO) applications. “We are witnessing the continued promise, utility, and proliferation of digital PCR in the analysis of liquid biopsies for use in therapeutic development and in patient diagnosis and monitoring of oncological disease,” says Philippe Mourère, President and CEO of Stilla Technologies. “Co-developing products with a strong assay partner in Atila will allow highly st